Novo Holdings A/S’s Edgewise Therapeutics EWTX Stock Holding History

Novo Holdings A/S’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217M	Hold	5,350,000	–	–	12.62%	1
2026 Q1	$169M	Hold	5,350,000	–	–	13.65%	1
2025 Q4	$133M	Hold	5,350,000	–	–	10.31%	2
2025 Q3	$86.8M	Hold	5,350,000	–	–	5.59%	5
2025 Q2	$70.1M	Hold	5,350,000	–	–	4.95%	6
2025 Q1	$118M	Buy	5,350,000 +350,000	+7%	+$9.18M	8.95%	3
2024 Q4	$134M	Sell	5,000,000 -549,900	-10%	-$17.5M	8.08%	4
2024 Q3	$148M	Sell	5,549,900 -794,530	-13%	-$15.8M	7.36%	4
2024 Q2	$114M	Buy	+6,344,430	New	+$111M	6.16%	6
2024 Q1	–	Sell	-6,071,703	Closed	-$66.4M	–	36
2023 Q4	$66.4M	Hold	6,071,703	–	–	4.1%	8
2023 Q3	$34.8M	Hold	6,071,703	–	–	2.57%	15
2023 Q2	$47.1M	Hold	6,071,703	–	–	3.64%	8
2023 Q1	$40.5M	Hold	6,071,703	–	–	2.67%	13
2022 Q4	$54.3M	Hold	6,071,703	–	–	3.39%	10
2022 Q3	$59.7M	Buy	6,071,703 +484,496	+9%	+$4.9M	2.85%	13
2022 Q2	$44.5M	Hold	5,587,207	–	–	2.19%	15
2022 Q1	$54.2M	Hold	5,587,207	–	–	2.86%	11
2021 Q4	$85.4M	Hold	5,587,207	–	–	4.04%	7
2021 Q3	$92.7M	Hold	5,587,207	–	–	4.8%	6
2021 Q2	$119M	Hold	5,587,207	–	–	5.29%	6
2021 Q1	$182M	Buy	+5,587,207	New	+$181M	7.5%	2

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Novo Holdings A/S's EWTX Position: Q2 2026 in Review

Novo Holdings A/S held its Edgewise Therapeutics (EWTX) position steady in Q2 2026 at 5,350,000 shares worth $217M. The position accounts for 12.62% of the portfolio, ranked #1.

Novo Holdings A/S first reported a position in EWTX in Q1 2021 and has held it in 21 quarters since. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

Novo Holdings A/S held 5,350,000 shares of Edgewise Therapeutics worth $217M as of Q2 2026.
Novo Holdings A/S left its Edgewise Therapeutics share count unchanged in Q2 2026.
Edgewise Therapeutics made up 12.62% of Novo Holdings A/S's portfolio in Q2 2026, its #1 holding.
Novo Holdings A/S first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 21 quarters since.
227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Novo Holdings A/S's 13F filing for Q2 2026, filed 14 Aug 2026.